Brrrr Calculator Excel

https://www.rigel.com › investors › news-events
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress Corporate Presentation May 2026 Corporate Presentation Recent Events View

https://www.rigel.com › pipeline
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and

https://www.rigel.com › contact-us
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and

https://www.rigel.com › investors
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering developing and providing novel small molecule drugs that significantly improve the lives of patients with immune

https://www.rigel.com › investors › news-events › press-releases › detail › rige…
Rigel s open label Phase 1b study of R289 is evaluating the safety tolerability pharmacokinetics and preliminary activity in patients with R R lower risk MDS NCT05308264

https://www.rigel.com › news-media › press-releases › detail › rigel-provides-b…
Rigel does not undertake any obligation to update forward looking statements whether written or oral that may be made from time to time whether as a result of new information future

https://www.rigel.com › investors › stock-data
Quote Stock Quote Rigel Pharmaceuticals Inc Nasdaq Global Select RIGL Price 1D 5D 1M 3M 6M 1Y 2Y 3Y 5Y 10Y 20Y

https://www.rigel.com › news-media › press-releases › detail › rigel-provides-f…
These forward looking statements include without limitation anticipated financial performance for 2026 anticipated timing and results from the clinical development of R289 Rigel s

https://www.rigel.com › investors › news-events › press-releases › detail › rige…
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU vepdegestrant an oral PROTAC for the Treatment of 2L ER HER2 ESR1m Advanced or Metastatic Breast Cancer